Last reviewed · How we verify

NCT06179901

The Effect of Early MSAT Treatment on Sciatica Caused by Traffic Accidents.

Completed NA Last updated 19 March 2025
What this trial tests

NA trial testing Integrative Korean Medicine Treatment in Sciatica in 40 participants. Completed in 15 October 2024.

Timeline
30 October 2023
Primary endpoint
6 October 2024
15 October 2024

Quick facts

Lead sponsorJaseng Medical Foundation
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment40
Start date30 October 2023
Primary completion6 October 2024
Estimated completion15 October 2024
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Jaseng Medical Foundation

Who can join

Adults 19 to 69, any sex, with Sciatica or Radiating Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators would like to conduct a pilot study prior to a practical randomized control study on the effectiveness of initial MSAT treatment on inpatients complaining of radiating pain and abnormal sensation in the lower extremities caused by traffic accidents.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effects of Hip Joint Motion-Style Acupuncture Treatment in Patients with Acute Radiating Leg Symptoms After Traffic Accidents: A Pilot Pragmatic Randomized Controlled Trial.
    Kim J, Kim SR, Seo M, Lee D, et al · · 2026 · PMID 42039236 · DOI 10.2147/jpr.s597299

Verify or expand the search:

Other recruiting trials for Sciatica

Currently open trials in the same condition.

Other Jaseng Medical Foundation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06179901.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing